Roche is among several drugmakers to announce large-scale U.S. investments in response to Trump's push to onshore pharmaceutical manufacturing.

U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion investment in the United States, the company said on Wednesday. Trump's order, signed on Monday, directs drugmakers to lower prices of brand-name medicines to align with those in other wealthy nations.

Roche Holding AG said it would need to reconsider planned US investments if President Donald Trump implements an executive order to cut prescription drug costs.